Refine
Year of publication
Document Type
- Article (218)
- Preprint (92)
- Conference Proceeding (4)
- Book (2)
- Review (2)
Language
- English (303)
- German (14)
- Multiple languages (1)
Has Fulltext
- yes (318)
Is part of the Bibliography
- no (318)
Keywords
- BESIII (9)
- Branching fraction (7)
- e +-e − Experiments (7)
- Lepton colliders (4)
- Particle and Resonance Production (4)
- Charm Physics (3)
- Charmed mesons (3)
- Electroweak interaction (3)
- Hadronic decays (3)
- e+-e− Experiments (3)
- Biomarkers (2)
- Branching fractions (2)
- CV9202 (2)
- Charm physics (2)
- Consensus (2)
- Diagnostik (2)
- Electroweak Interaction (2)
- Exotics (2)
- Früherkennung (2)
- Leptonic, semileptonic & radiative decays (2)
- MRI (2)
- Mammakarzinom (2)
- Nachsorge (2)
- Non-small cell lung cancer (2)
- Oncology (2)
- Particle decays (2)
- Polarization (2)
- Quarkonium (2)
- Rehabilitation (2)
- Richtlinie (2)
- SARS-CoV-2 (2)
- Spectroscopy (2)
- breast cancer (2)
- diagnosis (2)
- follow‑up (2)
- guideline (2)
- screening (2)
- ACL (1)
- ATM (1)
- Actin (1)
- Active middle ear implants (1)
- Activities of daily living (1)
- Acute inflammation (1)
- Acute myeloid leukemia (1)
- Alzheimer's disease (1)
- Animal models (1)
- Antiretroviral therapy (1)
- Antiretrovirals (1)
- Antirheumatic agents (1)
- Archaeogeophysics (1)
- Ascites (1)
- Auditory system (1)
- Austria (1)
- Automata theory (1)
- B cell receptor (1)
- BESIII detector (1)
- BI1361849 (1)
- BPDCN (1)
- Berci needle (1)
- Bevacizumab (1)
- Bhabha (1)
- Bone conduction devices (1)
- Born cross section measurement (1)
- BrainNet Europe consortium (1)
- Business strategy in drug development (1)
- Bypass liner (1)
- C1-INH (C1 inhibitor, C1-esterase inhibitor) (1)
- CAKUT (1)
- CDKN2A (1)
- COVID-19 (1)
- CP violation (1)
- CRISPR/Cas (1)
- Cancer (1)
- Capecitabine (1)
- Cardiomyopathy (1)
- Carex firma community (1)
- Carex sempervirens community (1)
- Caricion davallianae (1)
- Charmonia (1)
- Charmonium (1)
- Charmonium (-like) (1)
- Cherenkov counter: lead-glass (1)
- Child (1)
- Chondral Lesion (1)
- Cirrhosis (1)
- Claudin 5 (1)
- Clinical trial (1)
- Cognitive impairment (1)
- Cohort studies (1)
- Comparative effectiveness research (1)
- Complex I (1)
- Consensus statement (1)
- Covid-19 (1)
- Cross section (1)
- D meson (1)
- Dark photon (1)
- Dark sector (1)
- Dermatomyositis (1)
- Diabetes (1)
- Diagnosis (1)
- Diagnostic differentiation (1)
- Diagnostic markers (1)
- Dilated cardiomyopathy (1)
- Direct oral anticoagulation (1)
- Drug screens (1)
- Drug therapy (1)
- Dumon stents (1)
- Electromagnetic form factor (1)
- Electromagnetic form factors (1)
- Electron-pion identification (1)
- Endoscopy (1)
- Esophageal adenocarcinoma (1)
- Exercise (1)
- Experimental nuclear physics (1)
- Experimental particle physics (1)
- FAPI PET (1)
- FOS: Physical sciences (1)
- Fagus sylvatica (1)
- Festuco-Brometea (1)
- Fibre/foam sandwich radiator (1)
- Flavor changing neutral currents (1)
- Flavor symmetries (1)
- Flavour Physics (1)
- Form factors (1)
- Full waveform (1)
- Function (1)
- Gadobutrol (1)
- Gadopentate dimeglumine (1)
- Genome editing (1)
- Glioblastoma survival (1)
- HADES (1)
- HIV (1)
- HIV-1 (1)
- Haploidentical stem cell transplantation (1)
- Harz Mountains foothills (1)
- Health policy (1)
- Heart (1)
- Heart transplantation (1)
- Heavy ion storage ring (1)
- Hematology (1)
- Hepatitis C virus (1)
- Hereditary angioedema (1)
- High Energy Physics - Experiment (hep-ex) (1)
- Hsp70 (1)
- Hyperons (1)
- Hypofractionated radiotherapy (1)
- IHC (1)
- Immunomonitoring (1)
- Infinite games with perfect information (1)
- Initial state radiation (1)
- Interpretation (1)
- Intragastric balloon (1)
- Inversion (1)
- Invisible decays (1)
- Ionisation energy loss (1)
- KIR (1)
- KRAS (1)
- Lactic acidosis (1)
- Leukemias (1)
- Liver diseases (1)
- Liver transplantation (1)
- Low-molecular-weight heparin (1)
- MEDIC (1)
- MLL (1)
- Mena/VASP (1)
- Minimal residual disease (1)
- Mitochondrial disorder (1)
- Mixed hearing loss (1)
- Molecular diagnostic testing (1)
- Molinio-Arrhenatheretea (1)
- Multi-stakeholder approach (1)
- Multi-wire proportional drift chamber (1)
- NK cells (1)
- NMDA IgA/IgM antibodies (1)
- NMDA antibody (1)
- NRAS (1)
- Neonatal (1)
- Neural network (1)
- Neutrinos (1)
- Noninferiority (1)
- Obesity (1)
- Orbital electron capture (1)
- Ovarian cancer (1)
- Oxaliplatin (1)
- PDE‐5‐inhibitor (1)
- Parkinson disease (1)
- Particle and resonance production (1)
- Particle phenomena (1)
- Patellofemoral Joint (1)
- Pediatric (1)
- Physiotherapy (1)
- Preoperative radiochemotherapy (1)
- Prognosis (1)
- Proton (1)
- Pulmonary embolism (1)
- QCD (1)
- Quantum chromodynamics (1)
- RHIC (1)
- RNActive (1)
- Radiative decay (1)
- Rare decays (1)
- Rectal cancer (1)
- Registries (1)
- Renal lesions (1)
- Renal replacement therapy (1)
- Respiration (1)
- SCCHN (1)
- SLC20A1 (1)
- STAR (1)
- STIR (1)
- Semi-leptonic decays (1)
- Single particle decay spectroscopy (1)
- Single-leg hop for distance (1)
- Spectrin (1)
- Spin alignment (1)
- Surgery (1)
- TILs (1)
- TLR2/6 (1)
- TR (1)
- Technical data (1)
- Techniques Electromagnetic calorimeters (1)
- Therapeutic anticoagulation (1)
- Tomography (1)
- Tracking (1)
- Transition radiation detector (1)
- Treatment (1)
- Trigger (1)
- Two body weak decay (1)
- VE-cadherin (1)
- VEGF (1)
- VISTA (1)
- Validity (1)
- Vascular permeability (1)
- Violion caninae (1)
- Vitamin (1)
- Weight loss (1)
- Xenon-based gas mixture (1)
- Y states (1)
- acute myeloid leukemia (1)
- adult and elderly patients (1)
- aegean (1)
- airway (1)
- algorithms (1)
- alpine vegetation (1)
- angiogenesis (1)
- annual bleeding rate (1)
- arteriogenesis (1)
- artifacts (1)
- attention-deficit/hyperactivity disorder (ADHD) (1)
- auditory system (1)
- beech forests (1)
- bladder exstrophy-epispadias complex (1)
- blastic plasmacytoid dendritic cell neoplasm (1)
- blood flow recovery (1)
- bone-marrow (1)
- calorimeter: electromagnetic (1)
- center-of-mass energy (1)
- cerebral sinus and vein thrombosis (CVT) (1)
- charmonium-like states (1)
- cisplatin (1)
- cloacal malformation (1)
- coastal geomorphology (1)
- cohlear implant (1)
- collateral growth (1)
- combinatorics (1)
- comorbidity (1)
- component study (1)
- cone-beam computed tomography (CBCT) (1)
- cone-beam computer tomography (1)
- coronary artery disease (1)
- cytarabine dose (1)
- dE/dx (1)
- data quality (1)
- data structures (1)
- decompressive craniectomy (1)
- denervation (1)
- dimuon (1)
- dynamic vegetation model (1)
- e+e − annihilation (1)
- e+e⁻ − Experiments (1)
- e+e− Experiments (1)
- early tumor stages (1)
- effectiveness (1)
- elderly (1)
- electric and acustic stymulation (1)
- electrical resistivity tomography (1)
- electroencephalography (EEG) (1)
- electromagnetic navigation bronchoscopy (EMN, ENB) (1)
- electron-positron collision (1)
- electronics: readout (1)
- endothelial function (1)
- erectile dysfunction (1)
- femoral artery ligation (1)
- fibre: optical (1)
- fibrosis imaging (1)
- fluid shear stress (1)
- foraminifera (1)
- functional genetics (1)
- geophysical prospections (1)
- global warming (1)
- hadron spectroscopy (1)
- hadronic events (1)
- haemophilia A (1)
- hearing loss (1)
- helicity amplitude analysis (1)
- hierarchies and reducibilities (1)
- immunohistochemistry (1)
- inclusive J/ψ decays (1)
- inner ear (1)
- intracerebral hemorrhage (ICH) (1)
- intratumoral (1)
- kidney formation (1)
- lipiodol (1)
- local radiotherapy (1)
- logic (1)
- lung cancer (1)
- mRNA active cancer immunotherapy (1)
- mRNA vaccine (1)
- magnetic gradiometry (1)
- micropalaeontology (1)
- microwave ablation (1)
- mindfulness (1)
- monocytes (1)
- multicenter study (1)
- mutually exclusive mutations (1)
- mycorrhiza (1)
- nanoparticle (1)
- natural reforestation (1)
- neurofibrillary pathology (1)
- neuropathological diagnosis (1)
- neutralizing antibodies (1)
- next generation sequencing (1)
- nitrogen deposition (1)
- non-small cell lung cancer (1)
- non‐selective beta‐blocker (1)
- nuclear cardiology (1)
- number of J/ψ events (1)
- nutrient cycling (1)
- permanent plots (1)
- plant community assembly (1)
- plant functional traits (1)
- plant succession (1)
- plasma-derived factor VIII concentrate, prophylaxis (1)
- portal hypertension (1)
- prognosis (1)
- prognostic biomarker (1)
- psychotherapy process (1)
- pulmonary hypertension (1)
- radiation (1)
- randomized controlled trial (RCT) (1)
- reactive systems (1)
- recurrent mutations (1)
- retrospective trial (1)
- rolipram (1)
- solitary pulmonary nodule (1)
- species composition (1)
- species richness (1)
- specification and verification (1)
- spike protein (1)
- spiral ganglion cell (1)
- stability (1)
- stent (1)
- succession (1)
- tetraquark (1)
- therapeutic alliance (1)
- tracheobronchomalacia (1)
- transbronchial biopsy (TBB) (1)
- trigger efficiency (1)
- tropical montane forests (TMF) (1)
- urinary tract development (1)
- vaccination (1)
- vaccine-induced immune thrombotic thrombocytopenia (VITT) (1)
- variants of concern (1)
- vegetation classification (1)
- verification (1)
- von Willebrand disease (1)
- windthrow (1)
- zebrafish development (1)
- Λ+c baryon (1)
- Σ hyperon (1)
Institute
Objectives: An increasing number of treatment-determining biomarkers has been identified in non-small cell lung cancer (NSCLC) and molecular testing is recommended to enable optimal individualized treatment. However, data on implementation of these recommendations in the “real-world” setting are scarce. This study presents comprehensive details on the frequency, methodology and results of biomarker testing of advanced NSCLC in Germany.
Patients and methods: This analysis included 3,717 patients with advanced NSCLC (2,921 non-squamous; 796 squamous), recruited into the CRISP registry at start of systemic therapy by 150 German sites between December 2015 and June 2019. Evaluated were the molecular biomarkers EGFR, ALK, ROS1, BRAF, KRAS, MET, TP53, RET, HER2, as well as expression of PD-L1.
Results: In total, 90.5 % of the patients were tested for biomarkers. Testing rates were 92.2 % (non-squamous), 70.7 % (squamous) and increased from 83.2 % in 2015/16 to 94.2% in 2019. Overall testing rates for EGFR, ALK, ROS1, and BRAF were 72.5 %, 74.5 %, 66.1 %, and 53.0 %, respectively (non-squamous). Testing rates for PD-L1 expression were 64.5 % (non-squamous), and 58.5 % (squamous). The most common testing methods were immunohistochemistry (68.5 % non-squamous, 58.3 % squamous), and next-generation sequencing (38.7 % non-squamous, 14.4 % squamous). Reasons for not testing were insufficient tumor material or lack of guideline recommendations (squamous). No alteration was found in 37.8 % (non-squamous), and 57.9 % (squamous), respectively. Most common alterations in non-squamous tumors (all patients/all patients tested for the respective biomarker): KRAS (17.3 %/39.2 %), TP53 (14.1 %/51.4 %), and EGFR (11.0 %/15.1 %); in squamous tumors: TP53 (7.0 %/69.1 %), MET (1.5 %/11.1 %), and EGFR (1.1 %/4.4 %). Median PFS (non-squamous) was 8.7 months (95 % CI 7.4–10.4) with druggable EGFR mutation, and 8.0 months (95 % CI 3.9–9.2) with druggable ALK alterations.
Conclusion: Testing rates in Germany are high nationwide and acceptable in international comparison, but still leave out a significant portion of patients, who could potentially benefit. Thus, specific measures are needed to increase implementation.
Given the ongoing global SARS-CoV-2-vaccination efforts, clinical awareness needs to be raised regarding the possibility of an increased incidence of SARS-CoV-2-vaccine-related immune-mediated thrombocytopenia in patients with intracerebral hemorrhage (ICH) secondary to cerebral sinus and vein thrombosis (CVT) requiring (emergency) neurosurgical treatment in the context of vaccine-induced immune thrombotic thrombocytopenia (VITT). Only recently, an association of vaccinations and cerebral sinus and vein thrombosis has been described. In a number of cases, neurosurgical treatment is warranted for these patients and special considerations are warranted when addressing the perioperative coagulation. We, herein, describe the past management of patients with VITT and established a literature-guided algorithm for the treatment of patients when addressing the impaired coagulation in these patients. Increasing insights addressing the pathophysiology of SARS-CoV-2-vaccine-related immune-mediated thrombocytopenia guide physicians in developing an interdisciplinary algorithm taking into account the special considerations of this disease.
Community trait assembly in highly diverse tropical rainforests is still poorly understood. Based on more than a decade of field measurements in a biodiversity hotspot of southern Ecuador, we implemented plant trait variation and improved soil organic matter dynamics in a widely used dynamic vegetation model (the Lund-Potsdam-Jena General Ecosystem Simulator, LPJ-GUESS) to explore the main drivers of community assembly along an elevational gradient. In the model used here (LPJ-GUESS-NTD, where NTD stands for nutrient-trait dynamics), each plant individual can possess different trait combinations, and the community trait composition emerges via ecological sorting. Further model developments include plant growth limitation by phosphorous (P) and mycorrhizal nutrient uptake. The new model version reproduced the main observed community trait shift and related vegetation processes along the elevational gradient, but only if nutrient limitations to plant growth were activated. In turn, when traits were fixed, low productivity communities emerged due to reduced nutrient-use efficiency. Mycorrhizal nutrient uptake, when deactivated, reduced net primary production (NPP) by 61–72% along the gradient. Our results strongly suggest that the elevational temperature gradient drives community assembly and ecosystem functioning indirectly through its effect on soil nutrient dynamics and vegetation traits. This illustrates the importance of considering these processes to yield realistic model predictions.
Background & Aims: Phosphodiesterase‐5 inhibitors (PDE‐5‐I) are used for treatment of erectile dysfunction (ED), which is common in patients with cirrhosis. They may improve portal hypertension (PH), but contradictory data on efficacy and side‐effects have been reported. Non‐selective beta blockers (NSBB) reduce portal pressure, but might aggravate ED. Thus, we evaluated the combination of PDE‐5‐I with NSBB and its impact on PH and ED in experimental cirrhosis.
Methods: ED was assessed in cirrhotic patients (n = 86) using standardized questionnaire. Experimental cirrhosis was induced by bile‐duct‐ligation or carbon‐tetrachloride intoxication in rats. Corpus cavernosum pressure – a surrogate of ED ‐, as well as systemic and portal haemodynamics, were measured in vivo and in situ after acute administration of udenafil alone or in combination with propranolol. mRNA and protein levels of PDE‐5 signalling were analysed using PCR and western Blot.
Results: ED in humans was related to severity of liver disease and to NSBB treatment. PDE‐5 was mainly expressed in hepatic stellate cells and upregulated in human and experimental cirrhosis. Propranolol reduced corpus cavernosum pressure in cirrhotic rats and it was restored by udenafil. Even though udenafil treatment improved PH, it led to a reduction of mean arterial pressure. The combination of udenafil and propranolol reduced portal pressure and hepatic resistance without systemic side‐effects.
Conclusions: ED is common with advanced cirrhosis and concomitant NSBB treatment. The combination of PDE‐5‐I and NSBB improves ED and PH in experimental cirrhosis.
Background: Advanced non-small cell lung cancer (NSCLC) represents a significant unmet medical need. Despite advances with targeted therapies in a small subset of patients, fewer than 20% of patients survive for more than two years after diagnosis. Cancer vaccines are a promising therapeutic approach that offers the potential for durable responses through the engagement of the patient's own immune system. CV9202 is a self-adjuvanting mRNA vaccine that targets six antigens commonly expressed in NSCLC (NY ESO-1, MAGEC1, MAGEC2, 5 T4, survivin, and MUC1).
Methods/Design: The trial will assess the safety and tolerability of CV9202 vaccination combined with local radiation designed to enhance immune responses and will include patients with stage IV NSCLC and a response or stable disease after first-line chemotherapy or therapy with an EGFR tyrosine kinase inhibitor. Three histological and molecular subtypes of NSCLC will be investigated (squamous and non-squamous cell with/without EGFR mutations). All patients will receive two initial vaccinations with CV9202 prior to local radiotherapy (5 GY per day for four successive days) followed by further vaccinations until disease progression. The primary endpoint of the study is the number of patients experiencing Grade >3 treatment-related adverse events. Pharmacodynamic analyses include the assessment of immune responses to the antigens encoded by CV9202 and others not included in the panel (antigen spreading) and standard efficacy assessments.
Discussion: RNActive self-adjuvanted mRNA vaccines offer the potential for simultaneously inducing immune responses to a wide panel of antigens commonly expressed in tumors. This trial will assess the feasibility of this approach in combination with local radiotherapy in NSCLC patients.
Background: Preclinical studies demonstrate synergism between cancer immunotherapy and local radiation, enhancing anti-tumor effects and promoting immune responses. BI1361849 (CV9202) is an active cancer immunotherapeutic comprising protamine-formulated, sequence-optimized mRNA encoding six non-small cell lung cancer (NSCLC)-associated antigens (NY-ESO-1, MAGE-C1, MAGE-C2, survivin, 5T4, and MUC-1), intended to induce targeted immune responses.
Methods: We describe a phase Ib clinical trial evaluating treatment with BI1361849 combined with local radiation in 26 stage IV NSCLC patients with partial response (PR)/stable disease (SD) after standard first-line therapy. Patients were stratified into three strata (1: non-squamous NSCLC, no epidermal growth factor receptor (EGFR) mutation, PR/SD after ≥4 cycles of platinum- and pemetrexed-based treatment [n = 16]; 2: squamous NSCLC, PR/SD after ≥4 cycles of platinum-based and non-platinum compound treatment [n = 8]; 3: non-squamous NSCLC, EGFR mutation, PR/SD after ≥3 and ≤ 6 months EGFR-tyrosine kinase inhibitor (TKI) treatment [n = 2]). Patients received intradermal BI1361849, local radiation (4 × 5 Gy), then BI1361849 until disease progression. Strata 1 and 3 also had maintenance pemetrexed or continued EGFR-TKI therapy, respectively. The primary endpoint was evaluation of safety; secondary objectives included assessment of clinical efficacy (every 6 weeks during treatment) and of immune response (on Days 1 [baseline], 19 and 61).
Results: Study treatment was well tolerated; injection site reactions and flu-like symptoms were the most common BI1361849-related adverse events. Three patients had grade 3 BI1361849-related adverse events (fatigue, pyrexia); there was one grade 3 radiation-related event (dysphagia). In comparison to baseline, immunomonitoring revealed increased BI1361849 antigen-specific immune responses in the majority of patients (84%), whereby antigen-specific antibody levels were increased in 80% and functional T cells in 40% of patients, and involvement of multiple antigen specificities was evident in 52% of patients. One patient had a partial response in combination with pemetrexed maintenance, and 46.2% achieved stable disease as best overall response. Best overall response was SD in 57.7% for target lesions.
Conclusion: The results support further investigation of mRNA-based immunotherapy in NSCLC including combinations with immune checkpoint inhibitors.
Trial registration: ClinicalTrials.gov identifier: NCT01915524.
Glioblastoma (GBM) is a cancer type with high thrombogenic potential and GBM patients are therefore at a particularly high risk for thrombotic events. To date, only limited data on anticoagulation management after pulmonary embolism (PE) in GBM is available and the sporadic use of DOACs remains off-label. A retrospective cohort analysis of patients with GBM and postoperative, thoracic CT scan confirmed PE was performed. Clinical course, follow-up at 6 and 12 months and the overall survival (OS) were evaluated using medical charts and neuroradiological data. Out of 584 GBM patients, 8% suffered from postoperative PE. Out of these, 30% received direct oral anticoagulants (DOACs) and 70% low-molecular-weight heparin (LMWH) for therapeutic anticoagulation. There was no significant difference in major intracranial hemorrhage (ICH), re-thrombosis, or re-embolism between the two cohorts. Although statistically non-significant, a tendency to reduced mRS at 6 and 12 months was observed in the LMWH cohort. Furthermore, patients receiving DOACs had a statistical benefit in OS. In our analysis, DOACs showed a satisfactory safety profile in terms of major ICH, re-thrombosis, and re-embolism compared to LMWH in GBM patients with postoperative PE. Prospective, randomized trials are urgent to evaluate DOACs for therapeutic anticoagulation in GBM patients with PE.
Background: The importance of the Notch signaling in the development of glomerular diseases has been recently described. Therefore we analyzed in podocytes the expression and activity of ADAM10, one important component of the Notch signaling complex. Methods: By Western blot, immunofluorescence and immunohistochemistry analysis we characterized the expression of ADAM10 in human podocytes, human urine and human renal tissue. Results: We present evidence, that differentiated human podocytes possessed increased amounts of mature ADAM10 and released elevated levels of L1 adhesion molecule, one well known substrate of ADAM10. By using specific siRNA and metalloproteinase inhibitors we demonstrate that ADAM10 is involved in the cleavage of L1 in human podocytes. Injury of podocytes enhanced the ADAM10 mediated cleavage of L1. In addition, we detected ADAM10 in urinary podocytes from patients with kidney diseases and in tissue sections of normal human kidney. Finally, we found elevated levels of ADAM10 in urinary vesicles of patients with glomerular kidney diseases. Conclusions: The activity of ADAM10 in human podocytes may play an important role in the development of glomerular kidney diseases.
Wie es Eltern und ihren Kindern während der Corona-Pandemie geht, wie ihr aktuelles Wohlbefinden ist, was ihren Alltag kennzeichnet, wie die Passung zu den Regelungen der Kitabetreuung, Schulöffnung und auch der Arbeitgeber*innen ist – dies sind die Kernfragen der Onlinebefragung KiCo, welche im Zeitraum vom 24.04.2020 – 03.05.2020 durchgeführt wurde. Dieses Papier präsentiert erste Ergebnisse der Studie, an der über 25.000 Personen teilgenommen haben. Die Studie wurde umgesetzt vom Forschungsverbund "Kindheit – Jugend – Familie in der Corona-Zeit", der sich aus den Universitäten Hildesheim, Frankfurt und Bielefeld zusammensetzt.